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Abstract
Background: Low vitamin D status has been associated with a number of chronic diseases. For dyslipidemia, vitamin
D deficiency has been associated with higher low density lipoprotein-cholesterol (LDL-C) in a number of studies, but
with inconsistent results in clinical trials. The purpose of the present study is to explore the relative importance of
3-epi-25-hydroxyvitamin D (25(OH)D) as compared with the non-epimeric form in relation to serum lipid.
Method: This study used data from 1068 randomly selected volunteers in the Thai 4th National Health Examination
Survey (NHES IV). Serum 25(OH)D2, 25(OH)D3, 3-epi-25(OH)D2 and 3-epi-25(OH)D3 were analyzed by liquid
chromatography–tandem mass spectrometry.
Results: There was no association between serum total 25(OH)D and serum LDL-C. However, circulating
3-epi-25(OH)D3 was negatively related to serum LDL-C (r = −0.077, P <0.05), while no such association was
found for non-epimeric 25(OH)D3 (r =0.030, P = 0.33). On the other hand, both 3-epi-25(OH)D3 (r = 0.175,
P <0.001) and non-epimeric 25(OH)D3 (r = 0.142, P <0.001) were positively related to serum triglyceride (TRIG) levels.
In multiple linear regression models with age, gender, body mass index , urban residence, education,
hypertension and education as covariates, it was found that 3-epi-25(OH)D3 was independently associated with serum
LDL-C (beta = −0.12, P <0.01), while non-epimeric 25(OH)D3 was positively related to LDL-C (beta = 0.13, P = 0.002).
For TRIG, there were positive association with 3-epi-25(OH)D3 (beta = 0.27, P <0.001) and negative association
with non-epimeric 25(OH)D3 (beta = − 0.10, P = 0.011) independent of age, gender, urban resident and
education.
Conclusions: There is a discrepant association of 25(OH)D levels with serum lipids according to 25(OH)D
epimeric forms.
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Background
Vitamin D deficiency is highly prevalent even in tropical
countries [1, 2]. Lower vitamin D status has been associ-
ated with a number of chronic diseases, including meta-
bolic syndrome and cardiovascular disease [3]. With
regard to cardiovascular disease, vitamin D has been
shown in both cross-sectional and observational studies
to be related to its occurrence [4] and associated mortal-
ity. The causality of vitamin D in this regard, as well as
the underlying mechanisms involved, are still undeter-
mined. For dyslipidemia, vitamin D deficiency has also
been associated with higher levels of low-density lipo-
protein cholesterol in a number of studies, but with
inconsistent results from clinical trials [5].
The metabolism and action of vitamin D are complex,
and this may underlie the incongruence found among
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studies. C-3 epimers of vitamin D metabolites are
present in human circulation [6]. The biological func-
tions of the epimers as compared to native vitamin D
are not entirely settled; 3-epi-1α,25-dihydroxyvitamin D
(25(OH)2D) binds to the vitamin D receptor with less
affinity compared with its non-epimeric form [7]. How-
ever, 3-epi-1α,25(OH)2D suppresses parathyroid hormone
to a similar degree to its non-epimeric counterpart [8]. It
is unknown at present how C-3 epimers of vitamin D
metabolites and lipid metabolism are related. Toward this
end, we explored in the present study the relative import-
ance of 3-epi-25(OH)D as compared with the non-
epimeric form in their relationship to serum lipid levels.
Methods
Study population
This study used a subsample of 1068 participants who
were randomly selected by computer-generated random
numbers from the Thai 4th National Health Examination
Survey (NHES IV), conducted from August 2008
through March 2009 by the National Health Examin-
ation Survey Office, Health Systems Research Institute,
Thailand, with a sample size of 21,960 Thai individuals.
Details of sampling methods have been described previ-
ously [9]. Briefly, participants were randomly selects
from 21 provinces in four regions of Thailand and the
city of Bangkok. The present study drew on a subsample
of the data by dividing the total sample into 24 strata
based on sex, area of residence (urban or rural for each
of the four geographic regions and Bangkok, which was
regarded as an urban area only) and age-specific groups
(15–29, 30–44, 45–59, 60–69, 70–79 and ≥80 years of
age). In each stratum, serum samples were randomly
selected using statistical software from each region and
Bangkok; ultimately, a total of 1068 Thais were sampled.
Demographic data were collected by interviewers.
Weight and height were measured by trained field staff
using standard procedures. Body mas index (BMI) was
calculated as weight in kilograms divided by the square
of height in meters. Venous blood samples were ob-
tained from participants in the moring after overnight
fast. Fasting plasma glucose was measure on the same
day of field data collection. Fasting serum samples were
kept at −80 °C before analyses. This study complied with
the Declaration of Helsinki. It was also approved by the
ethics committee of Ramathibodi Hospital. All subjects
gave informed consent prior to the study.
Definition of diabetes and hypertension
Diabetes was defined as a previous diagnosis of diabetes
by a physician and having taken hypoglycemic medica-
tion during the prior 2 weeks, or with fasting plasma
glucose at the time of the survey ≥126 mg/dL.
Hypertension was defined as mean systolic blood pres-
sure equal to or greather than 140 mm/Hg or mean dia-
stolic blood pressure equal to or greater than 90 mmHg
or on medication to lower blood pressure in the past
two weeks.
Serum 25-hydroxyvitamin D (25(OH)D) measurement
All vitamin D metabolites were analyzed by LC-MS/MS
with an Agilent 1260 Infinity liquid chromatograph (Agi-
lent Technologies, Waldbronn, Germany) coupled to a
QTRAP® 5500 tandem mass spectrometer (AB SCIEX,
Foster City, CA, USA) using a MassChrom® 25-OH-
Vitamin D3/D2 in serum/plasma reagent kit including a
3-epi-25-OH-Vitamin D3/D2 upgrade diagnostics kit
(Chromsystems, Munich, Germany). All analyte values
of the calibrator and control were traceable to certified
substances and standard reference materials of the
National Institute of Standards and Technology. The
summation of serum 25(OH)D3, 25(OH)D2, 3-epi-
25(OH)D3 and 3-epi-25(OH)D2 was used to reflect vita-
min D status. The inter-assay and intra-assay coefficients
of variation of total serum 25(OH)D level were 6.2 and
9.3 %, respectively.
Biochemical measurement
Serum cholesterol, low-density lipoprotein cholesterol
(LDL-C), high-density lipoprotein cholesterol (HDL-C)
and triglyceride (TRIG) levels were analyzed on an auto-
mated biochemical analyzer (Dimension RxL; Dade
Behring, USA).
Statistical analyses
Data were expressed as mean ± SD for normal distribu-
tion or median and range for non-normal distribution.
The relative 3-epimer contribution (%) was used to ex-
press the amount of 3-epimer-25(OH)D as a percentage
of total 25(OH)D (the sum of 25(OH)D and 3-epi-
25(OH)D). The Kolmogorov–Smirnov test was used to
test for normality. A logarithmic transformation was
performed when the data did not follow a normal distri-
bution. Mann-Whitney U test was used for comparisons
of differences between two independent groups. Correla-
tions between two parameters were estimated by using
Spearman’s rank correlation coefficient. Multiple linear
regression models were used for assessing potential asso-
ciated factors. A P value less than 0.05 was considered
statistically significant. All analyses were performed
using Stata Statistical Software, Release 12 (StataCorp,
College Station, TX, USA).
Results
Clinical characteristics of the study population are de-
tailed in Table 1. Half of the samples were males and
53 % of all subjects resided in urban. Overll, mean age
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was 53 year old and mean 25(OH)D was 79.4 nmol/L.
More than half (56.4 %) of the subjects had primary edu-
cation and 35 % had secondary education level or above.
28.8 % of the participants had BMI >=25 kg/m2. Hyper-
tension and type 2 diabetes were found in 30.7 and
6.7 % of the subjects, respectively. The relative abun-
dance of 3-epi-25(OH)D compared with total 25(OH)D
(relative 3-epimer contribution) ranging from 1.74 to
24.49 %, with a median value of 6.48 %. Subjects with
vitamin D insufficiency, as defined by total 25(OH)D
levels less than 75 nmol/L, had lower the relative 3-
epimer contribution compared to those with vitamin D
sufficiency (median 6.34 %, ranged 1.74–14.15 % and
median 6.70, ranged 2.56–24.49, repectively) (P = 0.001).
Table 2 shows the association between serum lipid and
25(OH)D levels. There was no association between
serum total 25(OH)D and serum LDL-C. However,
circulating 3-epi-25(OH)D3 was negatively related to
serum LDL-C (r = −0.077, P <0.05), while no such asso-
ciation was found for non-epimeric 25(OH)D3 (r = 0.030,
P = 0.33). On the other hand, both 3-epi-25(OH)D3 (r =
0.175, P <0.001) and non-epimeric 25(OH)D3 (r = 0.142,
P <0.001) were positively related to serum TRIG levels.
In multiple linear regression models with age, gender,
BMI, urban residence, education, hypertension and
diabetes as covariates, it was found that 3-epi-
25(OH)D3 was independently associated with serum
LDL-C (beta = −0.12, P <0.01), while non-epimeric
25(OH)D3 was positively related to LDL-C (beta =
0.13, P = 0.002) (Table 3). For TRIG, there were posi-
tive association with 3-epi-25(OH)D3 (beta = 0.27, P <
0.001) and negative association with non-epimeric
25(OH)D3, (beta = −0.10, P = 0.011) independent of
age, gender, urban resident and education.
Discussion
In the present study using a subsample from a nationally
representatively survey, we demonstrated that 3-epi-
25(OH)D was negatively related to serum LDL-C but
positively related to serum TRIG. The association was
not likely to be affected by some underlying chronic
Table 1 Clinical Characteristics of the Study Population (n = 1068)
Characteristics Mean ± SD, or %
Age, years 53.4 ± 22.3
Male 49.8 %
Urban 53.9 %
Weight, kg 57.8 ± 12.7
Education




Height, cm 158.0 ± 8.5
BMI, kg/m2 23.1 ± 4.6









Cholesterol (mmol/L) 5.3 ± 1.2
LDL-C (mmol/L) 3.4 ± 1.0
HDL-C (mmol/L) 1.2 ± 0.3
Triglycerides (mmol/L) 1.6 ± 1.1
Serum non-epimeric 25(OH)D3 (nmol/L) 71.9 ± 20.2
Serum non-epimeric 25(OH)D2 (nmol/L) 1.7 ± 2.2
Serum 3-epi-25(OH)D3 (nmol/L) 5.5 ± 3.0
Serum 3-epi-25(OH)D2 (nmol/L) 0.19 ± 0.07
Total 25(OH)D (nmol/L) 79.4 ± 22.5
Table 2 Association between Serum Lipids and 25(OH)D Levels
Total 25(OH)D 3-epi-25(OH)D3 Non-epimeric 25(OH)D3 3-epi-25(OH)D2 Non-epimeric 25(OH)D2
Cholesterol r = 0.061 −0.008 0.064 −0.015 0.001
P = 0.045 0.786 0.036 0.616 0.962
LDL-C r = 0.016 −0.077 0.030 −0.032 −0.062
P = 0.604 0.012 0.328 0.289 0.044
HDL-C r = −0.063 −0.072 −0.067 0.052 0.035
P = 0.039 0.018 0.030 0.088 0.254
Triglycerides r = 0.161 0.175 0.142 −0.023 0.115
P = <0.001 <0.001 <0.001 0.456 <0.001
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diseases such as obesity, diabetes and hypertension in
particular, as they were controlled in the regression
model. Such a relationship was not readily apparent with
non-epimeric 25(OH)D levels, or even reversed. With
regard to the opposite effect of 3-epi-25(OH)D3 vs. its
non-epimeric counterpart on serum LDL-C from mul-
tiple regression analysis, it is possible that 3-epi-
25(OH)D3 may exert different influence on LDL-C me-
tabolism from that of 25(OH)D3. However, since 3-epi-
25(OH)D3 and the non-epimeric 25(OH)D3 levels were
correlated, it is also likely the discrepant finding may be
a result of multicollinearilty making the independent ef-
fect of each of these metabolites hard to determine in
the statistical analysis. For the different direction of asso-
ciation between 3-epi-25(OH)D with LDL-C and TRIG,
the underlying reason for the observation is not entirely.
However, since hepatic lipase is responsible for the con-
version of triglyceride rich very low density lipoprotein
to intermediate density lipoprotein and hence LDL, it is
conceivable that 3-epi-25(OH)D might reduce the acitiv-
ity of hepatic lipase rendering lower LCL-C levels but
higher TRIG levels.
Although the causal influence of vitamin D in the de-
termination of serum lipids cannot be concluded from
our study, the findings suggest that the effect of vitamin
D on lipid metabolism, if any, is likely to be partly
dependent on the epimeric forms of vitamin D metabo-
lites. Clinical studies looking at the independent effect of
25(OH)D epimers are scarce. Our finding is in keeping
with at least one recent clinical study showing that vita-
min D epimers, compared with total or non-epimeric
forms of 25(OH), are more related to a number of
disease states including type 2 diabetes, rheumatoid
arthritis and Alzheimer’s disease [10]. Dyslipidemia,
however, was not assessed in the study. With regard to
bone health, a more recent study in rodents showed that
the C-3α vitamin D epimer increases with higher doses
of vitamin D supplementation, without influencing bone
mass [11]. In addition, in healthy term infants who
received a vitamin D supplement, it was found that 3-epi-
25(OH)D3 was not associated with body composition [12].
Although the role of LDL-C in atherosclerosis is well
established, the role of raised TRIG in cardiovascular
disease is controversial. The adverse effect of hypertri-
glyceridemia on cardiovascular disease, if any, is more
likely to occur with serum triglycerides in the mild to
middle range, since at higher levels the lipoproteins
could be too large to enter the arterial intima [13, 14].
However, genetic studies, including those using the
Mendelian randomization approach, have suggested that
triglyceride-rich lipoproteins are a causal risk factor of
cardiovascular disease [15, 16]. The effect of vitamin D
on cardiovascular disease and mortality has been sug-
gested. A recent meta-analysis showed the influence of
vitamin D3 on mortality, while vitamin D2 did not ap-
pear to have any effect [17]. A more recent systematic
review also demonstrated the effect of vitamin D on
mortality associated with various causes, including those
related to cardiovascular disease and cancer [18]. In
addition, Ciccone et al., has found a significant correl-
ation of vitamin D deficiency with mortality for major
cardiovascular events such as heart failure, myocardial
infarction, sudden cardiac death, stroke, atrial fibrilla-
tion, and peripheral vascular disease [19]. The causal
role of vitamin D, however, in cardiovascular diseases
and others is controversial [20]. Likewise, the causal re-
lationship between vitamin D epimers and dyslipidemia
as well as other disease states is unclear. Nevertheless,
there are indications of biological possibility. The epimer
3-epi-25(OH)D3 can undergo 1α-hydroxylation to form
3-epi-1,25(OH)2D3, which can bind to the vitamin D re-
ceptor and activate gene transcription [21]. It appears
that 3-epi-1,25(OH)2D3 is nearly potent as 1,25(OH)2D3
in suppressing parathyroid hormone secretion but has
significantly reduced calcemic effects [8, 22].
The observed correlation between 3-epi-25(OH)D and
serum lipids in the present study may be part of the
underlying basis for the association between vitamin D
Table 3 Multiple Linear Regression According to Predictive Factors and Serum Lipids
Variable Cholesterol LDL-C HDL-C Triglycerides
Beta P-value Beta P-value Beta P-value Beta P-value
Age 0.22 <0.001 0.23 <0.001 −0.08 0.075 0.07 0.1061
Male −0.17 <0.001 −0.16 <0.001 −0.17 <0.001 0.04 0.211
BMI 0.17 <0.001 0.15 <0.001 −0.22 <0.001 0.20 <0.001
Urban/rural 2.33 0.401 0.02 0.636 0.10 0.002 −0.03 0.344
Education 0.44 0.287 0.04 0.367 0.14 <0.001 −0.05 0.222
Hypertension 7.53 0.024 0.01 0.788 0.03 0.471 0.15 <0.001
Diabetes 0.42 0.940 −0.03 0.281 −0.03 0.394 0.07 0.035
3-epi-25(OH)D3 −0.02 0.987 −0.12 0.003 0.05 0.170 0.27 <0.001
Non-epimeric 25(OH)D3 0.10 0.035 0.13 0.002 0.01 0.841 −0.10 =0.011
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status and cardiovascular health. A small study found an
association between vascular health indices and serum
total and free 25(OH)D in adolescents [23].
Despite the promising effect of vitamin D on serum
lipids, interventional trials with vitamin D have generally
failed to demonstrate a causal association. A number of
previous studies have investigated the relationship be-
tween vitamin D status and serum lipids. For example,
calcium/vitamin supplementation was found to have a
favorable effect on serum lipids in the Women’s Health
Initiative study [24]. A small clinical trial using vitamin
D-fortified skimmed milk found a reduction in blood
pressure but no beneficial effect of the intervention on
serum lipids [25]. However, blood pressure reduction
was not found in another study of vitamin D supple-
mentation [26]. Besides the probable difference in study
design and study populations, it is likely that between-
subject differences in the proportion of the epimeric
versus non-epimeric forms of vitamin D after supple-
mentation may partly be accountable for the inconsist-
ent results. Further clinical trials looking at the effect of
vitamin D should probably include the assessment of
vitamin D epimers.
A number of limitations are present in this study. The
study was cross-sectional in nature and the causative
role of vitamin D epimers, if any, could not be readily
determined. Moreover, although none of the subjects in
the present study were taking lipid-lowering agents, data
regarding other concurrent medications or supplements,
dietary intake of vitamin D and food consumption which
may influence serum lipids or vitamin D status and the
association were not available. Further studies control-
ling for such variables are therefore warranted.
Conclusion
This is the first report of the discrepant association of
25(OH)D levels with serum lipids according to 25(OH)D
epimeric forms. The relative amount of 3-epi- versus
non-epimeric 25(OH)D after vitamin D supplementation
may be attributable to the discrepant findings among
clinical trials.
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